Abstract 9929: Medium-Term Repeated Administration of Miglitol Improves Vascular Endothelial Dysfunction in Diabetic Patients with Coronary Artery Disease - Evaluation Using Flow-Mediated Dilatation
Background: Repeated postprandial hyperglycemia may play an important role in the development of atherosclerosis by suppressing vascular endothelial function. Although miglitol suppresses the elevation of blood glucose levels shortly after a meal more than other α-glucosidase inhibitors, the effect of medium-term repeated administration of miglitol on endothelial dysfunction is unknown.
Methods: Fifty type 2 diabetic patients with coronary artery disease (CAD) were enrolled in the present study. The patients were randomly divided into two groups: the first was treated with miglitol (M-group, 150mg/day) and the second with voglibose (V-group, 0.6mg/day) for 3 months. Blood chemistry (lipid and blood glucose profiles, hemoglobinA1c, 1,5-anhydroglucitol, serum insulin levels, and C-reactive protein) and flow-mediated dilatation (FMD), a surrogate marker of vascular endothelial function, were measured at the beginning and end of the trial period.
Results: Patient characteristics and blood chemistry of the two groups were similar at the beginning of the trial. At the end of the trial, hemoglobinA1c decreased in both groups, but the improvement of 1,5-anhydroglucitol levels in M-group patients were significantly higher than in V-group patients(14.5 ± 8.7 μ g/ml to 21.3 ± 9.8 μ g/ml in the M-group vs. 16.2 ± 8.3 μ g/ml to 17.6 ± 8.6 μ g/ml in the V-group) .Insulin resistance index (serum insulin levels × fasting blood sugar/405), CRP and %FMD also improved in M-group but not in V-group patients (2.8±1.9% to 5.3±2.1%, P<0.0001 vs. 3.0±3.7% to 3.2±1.7%, P=0.36).
Conclusions: Medium-term Repeated administration of miglitol improved vascular endothelial dysfunction by strongly suppressing postprandial hyperglycemia. Miglitol may have vasoprotective and anti-atherogenic effects in type 2 diabetic patients with CAD.
- © 2011 by American Heart Association, Inc.